PCSK9 and familial hyperaldosteronism: Therefore, we conducted a systematic review, and meta-analysis if appropriate, to examine the cumulative evidence on the clinical efficacy and safety of the PCSK9 inhibitors evolocumab and alirocumab among pediatric patients diagnosed with FH to provide the basis for clinical practice.